- Home
- PAXS vs XERS Comparison
PAXS vs XERS Comparison
Compare PAXS & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAXS
- XERS
- Stock Information
- Founded
- PAXS 2021
- XERS 2005
- Country
- PAXS United States
- XERS United States
- Employees
- PAXS N/A
- XERS N/A
- Industry
- PAXS Investment Managers
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- PAXS Finance
- XERS Health Care
- Exchange
- PAXS Nasdaq
- XERS Nasdaq
- Market Cap
- PAXS 677.7M
- XERS 752.7M
- IPO Year
- PAXS N/A
- XERS 2018
- Fundamental
- Price
- PAXS $15.09
- XERS $5.11
- Analyst Decision
- PAXS
- XERS Strong Buy
- Analyst Count
- PAXS 0
- XERS 6
- Target Price
- PAXS N/A
- XERS $6.25
- AVG Volume (30 Days)
- PAXS 195.0K
- XERS 2.0M
- Earning Date
- PAXS 01-01-0001
- XERS 08-07-2025
- Dividend Yield
- PAXS 11.72%
- XERS N/A
- EPS Growth
- PAXS N/A
- XERS N/A
- EPS
- PAXS N/A
- XERS N/A
- Revenue
- PAXS N/A
- XERS $222,551,000.00
- Revenue This Year
- PAXS N/A
- XERS $35.03
- Revenue Next Year
- PAXS N/A
- XERS $18.31
- P/E Ratio
- PAXS N/A
- XERS N/A
- Revenue Growth
- PAXS N/A
- XERS 29.88
- 52 Week Low
- PAXS $12.57
- XERS $2.10
- 52 Week High
- PAXS $15.93
- XERS $6.07
- Technical
- Relative Strength Index (RSI)
- PAXS 49.31
- XERS 61.48
- Support Level
- PAXS $15.05
- XERS $4.62
- Resistance Level
- PAXS $15.19
- XERS $5.39
- Average True Range (ATR)
- PAXS 0.09
- XERS 0.21
- MACD
- PAXS 0.00
- XERS 0.07
- Stochastic Oscillator
- PAXS 39.13
- XERS 71.72
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).